1 Mar 2022 13:18
GlaxoSmithKline plcΒ (theΒ 'Company')
Transaction notification
Β
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the exercise of options granted on 29 November 2018 at the option price of Β£12.09 per Ordinary Share under the Company's ShareSave Plan.Β | |||
c) | Price(s) and volume(s) | Β | Price(s) | Volume(s) | Β |
Β | Β£12.09 | 744 | Β | ||
Β | Β | Β | Β | ||
d) | Aggregated information Β Β | N/A (single transaction) | |||
Aggregated volume Price | Β | ||||
e) | Date of the transaction | 2022-02-25 | |||
f) | Place of the transaction Β | London Stock Exchange (XLON) | |||
Β
Β
Β
Follow the stocks